Choroidal Detachment following an Intravitreal Injection in a Patient with Vogt-Koyanagi- Harada Disease

Ocul Immunol Inflamm. 2021 Feb 17;29(2):396-398. doi: 10.1080/09273948.2019.1677919. Epub 2019 Oct 30.

Abstract

Purpose: To report a unique case of choroidal detachment following an intravitreal injection in a patient with Vogt-Koyanagi-Harada (VKH) disease.Methods: A 33-year-old male, a known case of chronic VKH disease for 9 years developed an inflammatory choroidal neovascular membrane (CNVM) in the right eye. Following an intravitreal ranibizumab injection, he reported loss of vision 2 days later. Clinical examination revealed hypotony with annular serous choroidal detachment.Results: Following an intensive systemic corticosteroid therapy, there was a complete resolution of choroidal detachment and restoration of visual acuity at 1 week of follow up. The subretinal fluid and cystic spaces due toCNVM also resolved completely.Conclusion: This is the first report of a patient with VKH disease developing choroidal detachment following an uncomplicated intravitreal injection of ranibizumab for an inflammatory CNVM.

Keywords: Choroidal detachment; Vogt-Koyanagi-Harada disease; choroidal neovascular membrane; intravitreal injection; ranibizumab.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Angiogenesis Inhibitors / administration & dosage
  • Angiogenesis Inhibitors / adverse effects*
  • Choroid / diagnostic imaging*
  • Choroidal Effusions / diagnosis
  • Choroidal Effusions / etiology*
  • Fluorescein Angiography / methods*
  • Fundus Oculi
  • Humans
  • Intravitreal Injections / adverse effects
  • Male
  • Ranibizumab / administration & dosage
  • Ranibizumab / adverse effects*
  • Tomography, Optical Coherence / methods*
  • Uveomeningoencephalitic Syndrome / diagnosis
  • Uveomeningoencephalitic Syndrome / drug therapy*
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Visual Acuity

Substances

  • Angiogenesis Inhibitors
  • Vascular Endothelial Growth Factor A
  • Ranibizumab